title: Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight.
abstract: Treat-to-target is a therapeutic strategy aimed at improving disease outcome through the achievement of shared treatment goals, which has dramatically ameliorated the prognosis of widespread disorders, such as hypertension or diabetes. Conversely, efforts to delineate treat-to-target in systemic lupus erythematosus (SLE) have failed in pinpointing common goals and treatment strategies, probably because of disease heterogeneity and lack of measurable biomarkers predicting disease course and ensuring a safe treatment tapering during quiescence. Given the detrimental effects of persistent disease activity and protracted corticosteroid therapy on patients' outcome in lupus, disease remission should be pursued whenever possible. Fortunately, clinical remission is currently realistic for a greater number of patients than it was in the past, yet tight monitoring is required in order for patients to benefit from disease- and corticosteroid-free intervals, while minimizing the risk of disease flares. In everyday practice, patients should be brought to the lowest level of disease activity ensuring a significant benefit over a persistently active disease, being either clinical remission or low disease activity.
authors: Division of Rheumatology, Department of Medicine, University of Padova, Padova, Italy adoria@unipd.it.
authors: A
authors: A
authors: Doria
authors: Division of Rheumatology, Department of Medicine, University of Padova, Padova, Italy.
authors: M
authors: M
authors: Gatto
authors: Division of Rheumatology, Department of Medicine, University of Padova, Padova, Italy.
authors: L
authors: L
authors: Iaccarino
authors: Division of Rheumatology, Department of Medicine, University of Padova, Padova, Italy.
authors: L
authors: L
authors: Punzi
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use*; D019468:Disease Management; D018450:Disease Progression; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D011379:Prognosis; D012074:Remission Induction; D012720:Severity of Illness Index
chemical_list: D000305:Adrenal Cortex Hormones
keywords: Systemic lupus; corticosteroid tapering; low disease activity; outcome; remission; target